What is HC Wainwright’s Estimate for MLYS FY2024 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for Mineralys Therapeutics in a research note issued on Tuesday, November 12th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($3.83) per share for the year, down from their previous forecast of ($3.22). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($3.50) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2024 earnings at ($1.14) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($3.41) EPS, FY2027 earnings at ($3.54) EPS and FY2028 earnings at ($1.85) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the previous year, the firm posted ($0.57) EPS.

Mineralys Therapeutics Trading Down 5.7 %

Shares of Mineralys Therapeutics stock opened at $11.48 on Thursday. The business’s fifty day simple moving average is $12.99 and its 200 day simple moving average is $12.65. Mineralys Therapeutics has a 12 month low of $5.85 and a 12 month high of $16.91. The firm has a market capitalization of $571.36 million, a P/E ratio of -3.62 and a beta of 1.71.

Institutional Trading of Mineralys Therapeutics

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in Mineralys Therapeutics in the 3rd quarter valued at approximately $110,000. China Universal Asset Management Co. Ltd. grew its position in shares of Mineralys Therapeutics by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock valued at $116,000 after purchasing an additional 3,732 shares in the last quarter. Bellevue Group AG bought a new stake in shares of Mineralys Therapeutics during the 1st quarter valued at $119,000. Federated Hermes Inc. lifted its holdings in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after purchasing an additional 6,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Mineralys Therapeutics in the 2nd quarter worth about $145,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider David Malcom Rodman sold 25,482 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total value of $382,994.46. Following the sale, the insider now directly owns 135,974 shares in the company, valued at approximately $2,043,689.22. The trade was a 15.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now owns 236,854 shares of the company’s stock, valued at $3,214,108.78. This represents a 4.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,510 shares of company stock valued at $735,431 in the last ninety days. 33.24% of the stock is currently owned by insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.